Tableting agents or pharmaceutical excipients (PE) is a major component of a wide range of synthetic drug preparations, including inhalation medications, over-the-counter medications, oral medications, and medications for treating skin conditions such as acne and psoriasis. Tableting agents are highly processed chemical substances used to enhance the therapeutic properties of a pharmaceutical product. There is very little data on the long-term health consequences of continuous exposure to these chemicals. As with many chemical compounds, the extent of their side effects is dependent upon the dose, frequency, and exposure period.
Owing to the increase of chronic diseases such as diabetes, the demand in the global tableting agent market is also increasing. For instance, according to World Health Organization, around 463 million individuals in the world are diagnosed with diabetes. Moreover, the widely diversified uses of tableting agents owing to their abilities to identify properties such as cohesion and stabilization are creating propulsion in the global tableting agent market.
The Food and Drug Administration (FDA) has defined several classes of pharmaceutical excipients based on the extent of their synthetic character. The most popular and generic names for these chemicals are listed in Table I. These products vary greatly in the concentration of the additives and binders they contain and their ability to penetrate various biological membranes. The majority of pharmaceutical products in the United States contain at least one of these three types of additives. Some products, such as liposomes and polyethylene glycol, are more common than others and have become more widely used in the world.
However, active pharmaceutical ingredients and tableting agents can have few incompatibilities, which can result in drug-tableting agent interaction and reduce the potency of the drug. This is the main restraining factor to the growth of the global tableting agent market. Not all pharmaceutical products are formulated to meet the safety standards required by the FDA. Many products may not be labeled as 'Pharmaceutical' because they do not contain active pharmaceutical ingredients. This includes so-called dietary supplements that are generally considered safe to use even if not specifically intended to treat a disease, and Botox, which is largely unregulated and considered untested, even among the cosmetic industry. When choosing a pharmaceutical filler, it is important to ensure that the product meets the strict regulations regarding cosmetics and pharmaceuticals.
Owing to the focus of pharmaceutical companies on the development of advanced technologies and implementation of new tableting agents in North America, the region is experiencing high demand in the tableting agent market. For instance, in 2019, Millipore Sigma introduced a new tableting agent known as Partech COAT. Owing to these factors, there has been some significant development in the global tableting agent market. For instance, in February 2020, ReForm Biologics LLC, along with MilliporeSigma announced their collaboration to reform the usage of tableting agents in bio-therapeutics.